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Summary
Recognition of self is essential for repertoire selec-
tion, immune regulation, and autoimmunity and may
be a consequence of infection. Self-induced recogni-
tion may represent the escape mechanism adopted
by pathogens but may also incite autoimmune dis-
eases. Here, we show that bacterial infection may pro-
mote activation of T cells reactive to self-glycosphin-
golipids (self-GSL). CD1+ antigen-presenting cells
(APCs) infected with bacteria (Escherichia coli, Bacil-
lus subtilis, Staphylococcus aureus, or Mycobacte-
rium bovis-Bacillus Calmette Guerín [BCG]) or treated
with the bacterial components lipopolysaccharide, li-
poteichoic acid, or Pam3CysSerLys4 (P3CSK4) lipo-
peptide acquire the capacity to stimulate self-GSL-
specific T cells to cytokine release. Immediately after
infection, APCs increase the endogenous GSL syn-
thesis and stimulate GSL-specific T cells in a CD1-
and T cell receptor (TCR)-dependent manner. This
stimulation may contribute to inflammatory responses
during bacterial infections and may predispose in-
dividuals to autoimmune diseases.*Correspondence: gennaro.delibero@unibas.ch
6 Present address: Molecular Biomedicine, Department of Environ-
mental Sciences, Swiss Federal Institute of Technology Zurich, Zu-
rich, Switzerland.
7 Present address: Center of Molecular Immunology, Havana, Cuba.Introduction
The immune system is endowed with an intrinsic ca-
pacity to recognize self-antigens. This is particularly
true for T lymphocytes, whose TCRs are positively se-
lected by low-affinity interactions with self-peptides in
the thymus. Therefore, it is rather common to find auto-
reactive T cells in the periphery of normal donors. This
raises an important difference between autoimmunity
in general and autoimmune diseases (Lipsky, 2001;
Marrack et al., 2001). Indeed, it is difficult to understand
the reason why autoimmune phenomena degenerate
into an autoimmune disease in only a few cases (Be-
noist and Mathis, 2001; Davidson and Diamond, 2001).
Some autoimmune diseases are associated with pre-
ceding infection. Infectious agents and microbial prod-
ucts are suspected to induce autoimmune diseases
essentially by two mechanisms: antigen specific and
antigen nonspecific. The first type of mechanism relies
on epitope mimicry; some microbial products share im-
munogenic determinants with self-molecules, and the
immune response against the infectious agent cross-
reacts with the self-antigen (Oldstone, 1998). Such a
mechanism has been implicated in the development of
Guillain-Barré syndrome (GBS), after infection with the
gastrointestinal pathogen Campylobacter jejuni, due to
mimicry of gangliosides by the bacterial lipopolysac-
charide (LPS) (Moran and Prendergast, 2001; Moran et
al., 2002) and in the development of gastric atrophy as-
sociated with Helicobacter pylori infection due to LPS
or peptide mimicry of the gastric H+K+-ATPase (Amedei
et al., 2003; Appelmelk et al., 1997). Another autoim-
mune disease in which antigenic mimicry has been sus-
pected to play an important pathogenetic role is multi-
ple sclerosis (MS) (Wucherpfennig and Strominger,
1995). Studies performed in the experimental autoim-
mune encephalomyelitis (EAE) model have shown that
a large number of microbial peptides may activate a
single myelin-basic protein-specific TCR and may also
induce the disease (Grogan et al., 1999).
The antigen-nonspecific theory instead involves sev-
eral mechanisms. Upon infection, tissue destruction
may cause the release of hidden self-antigens that acti-
vate the autoimmune response. In addition, microbial
products may positively influence the presentation of
self-antigens by upregulating presenting and costimu-
latory molecules (Janeway, 2002) and/or by facilitating
the migration of APCs to secondary lymphoid organs
(Banchereau et al., 2000). Some microbes produce
molecules with superantigen characteristics, and it has
been speculated that they may induce a polyclonal lym-
phocyte activation responsible for the autoimmune at-
tack (Proft and Fraser, 2003). Finally, innate immune re-
sponses may also participate in the initiation and
persistence of autoimmunity (Eriksson et al., 2003; Shi
et al., 2001) or may change the “inflammatory status”
of the affected organ, thus leading to initiation of the
autoimmune disease (Lang et al., 2005).
In this study, we describe a third possible mecha-
nism, different from antigen mimicry, in which bacterial
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764infections induce activation of autoreactive T cells. We
find that infections with different strains of bacteria and
stimulation with different microbial cell wall and mem-
brane components induce increased synthesis of self-
glycolipids in APCs, which thus acquire the capacity to
stimulate CD1-restricted self-glycolipid-specific T cells.
This bacteria-induced self-recognition leads to efficient
stimulation of autoreactive T lymphocytes, which may
contribute to some autoimmune responses.
Results
DCs Infected with Bacteria or Treated with Microbial
Products Stimulate Self-Glycolipid-Reactive T cells
We investigated whether bacterial infection affects the
capacity of APCs to stimulate autoreactive GSL-spe-
cific and CD1-restricted T cells. Two CD1a-restricted
and two CD1b-restricted T cell clones were used in
these studies. The two CD1a-restricted clones and the
one CD1b-restricted clone were specific for sulfatide
(Shamshiev et al., 2002), and the second CD1b-
restricted clone was specific for ganglioside GM1
(Shamshiev et al., 1999, 2000). E. coli-, B. subtilis-,
S. aureus-, or M. bovis BCG-infected immature dentritic
cells (DCs) stimulated both CD1a-restricted (Figure 1,
right column) and CD1b-restricted (Figure 1, left col-
umn) T cells to secrete IFN-γ in the absence of exoge-
nously added, specific GSL. Infection with all tested
bacteria induced maximal stimulation at the bacteria to
APC ratio of 1:1 (data not shown). In some cases, IFN-γ
was released in small amounts by T cell clones coculti-
vated with the bacteria in the absence of DCs and
F
by T cells cocultivated with uninfected DCs. Small t
amounts of this cytokine were detected only rarely t
when DCs were infected with bacteria in the absence D
of T cells. Because human DCs do not release IFN-γ, l
rthis is likely due to the presence of a few contaminating
iT cells in these particular DC preparations.
aWe next investigated whether bacterial products
present in the membrane or cell wall of different bacte-
ria could mimic the effects of bacterial infection. DCs
rwere incubated with different doses of LPS (present in
tgram-negative bacteria) and isolated from E. coli, or
hwith lipoteichoic acid (LTA, which is present in all gram-
rpositive bacteria), or with the synthetic lipopeptide
pP3CSK4 (which resembles the anchor structure of bac-
tterial lipoproteins (Sankaran et al., 1995), and were sub-
bsequently used to activate CD1-restricted T cells. Like
Ebacteria-infected DCs, DCs treated with these bacterial
Sproducts activated GSL-specific T cells. This activation
Dwas dose-dependent and occurred in the absence of
texogenous GSL-added antigens (Figure 2). No cytokine
crelease by DCs or by T cells alone occurred upon treat-
ument with bacterial products (data not shown), confirm-
wing that T cells are efficiently activated only when stim-
aulated with treated DCs. The bacterial products showed
4different stimulatory capacities, with LPS and P3CSK4
active at a dose of 1 ng/ml and LTA active only at the
γhigh dose of 10 g/ml. Because the tested compounds
thave structures that are completely different from those
wof the self-GSL recognized by T cells, the observed ef-
tfect is very unlikely to be attributable to mimicry.
Moreover, because LPS is the bacterial component (igure 1. CD1-Restricted and Self-GSL-Specific T Cells Respond
o the DCs Infected with E. coli, B. subtilis, S. aureus, or BCG in
he Absence of Exogenously Added Specific Antigen
Cs were infected with bacteria, then washed and used to stimu-
ate the CD1a-restricted K34A12.1 (right column) and the CD1b-
estricted GG33A (left column) T cell clones. Released IFN-γ ± SD
s shown. Similar results were obtained in three experiments and
lso when released IL-4 was measured (data not shown).esponsible for many cellular responses during infec-
ion with gram-negative bacteria, we further studied
ow it induces such a strong stimulation of CD1-
estricted T cells. We tested whether the capacity to
romote DC recognition by T cells is shared by struc-
urally different LPSs. LPSs with different lipid and car-
ohydrate moieties and derived from different strains of
. coli, Campylobacter jejuni, Helicobacter pylori, and
almonella typhimurium were investigated (Table 1).
Cs treated with different LPSs showed similar stimula-
ory capacity on both CD1a- and CD1b-restricted T
ells and stimulated the release of IFN-γ and IL-4 (Fig-
re 3). Furthermore, similar results were also obtained
ith LPSs from C. jejuni HS:19, AZR649, HS:2 aerotoler-
nt, HS:3, and HS:6 and from H. pylori NCTC 11637,
42, and J178 (data not shown).
As a control, TCR αβ MHC class II-restricted and TCR
δ clones were incubated with LPS-treated APCs and
ested for IFN-γ release. In both cases, no activation
as observed despite these clones responding when
he appropriate ligands were included in the assay
data not shown). The unique activation of self-GSL-
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765Figure 2. CD1b-Restricted and Self-GSL-Specific T Cell Clones Re-
act to DCs Treated with Different Microbial Components in the Ab-
sence of Specific Antigen
DCs were incubated with LPS of E. coli O55:B5 (top panels),
P3CSK4 (middle), or LTA (bottom panels) for 2 hr before addition of
sulfatide-specific DS1C9b T cells or GM1-specific GG33A T cells.
Released IFN-γ ± SD is shown. Results are representative of seven
experiments. Similar results were obtained when released IL-4 was
measured (data not shown).specific T cells and not of other T cells indicates that
this antigen specificity is important.
To study the relative importance of LPS carbohydrate
and lipidic moieties, we tested the activity of modified
LPS and of free lipid A. LPSs of three different C. jejuni
strains (16971.94GSH, 260.94RXH, and 176.83) were
methylated and, thus, modified in their carbohydrate
moieties. DCs treated with methylated LPS did not acti-
vate CD1-restricted T cells (Figure 3C). When LPS from
C. jejuni 260.94RXH was acetylated, again modifying
the carbohydrate part, a strong reduction of activation
was observed, even at doses as high as 10 g/ml (Fig-
ure 3D). Next, LPSs from two different C. jejuni strains
(16971.94GSH and 28134.94GSH) and the H. pylori
strain AF1 were delipidated, thereby maintaining an in-
tact carbohydrate part. DCs treated with these carbo-
hydrate moieties did not activate CD1-restricted T cells
(Figure 3D). Furthermore, two types of lipid A, isolated
from E. coli and Salmonella minnesota, respectively,
were not stimulatory even at doses as high as 50 g/ml (Figure 3D). These findings show that both the car-
bohydrate and lipid A moieties within intact LPSs are
required to induce in APC the capacity to activate auto-
reactive T cells.
Requirements for T Cell Activation
by LPS-Treated APC
To determine whether the T cell stimulatory effect of
LPS is mediated through specific antigen presentation
by CD1 molecules and TCR engagement, blocking ex-
periments with anti-CD1a and anti-CD1b mAbs were
performed. These mAbs, but not irrelevant mAbs, inhib-
ited activation of the T cells restricted by CD1a and
CD1b, respectively (Figures 4A and 4B). Furthermore,
addition of anti-CD3 Fab fragments reduced T cell ac-
tivation, suggesting that TCR engagement is necessary
for this T cell response. To confirm the CD1 restriction,
we also tested THP-1 cells, a monocyte-like cell line,
transfected with the CD1B gene. Upon treatment with
all tested LPSs, CD1B-transfected THP-1 cells, but not
THP-1-mock transfected cells, stimulated the glyco-
lipid-reactive T cells (Figure 4C). Taken together, these
data indicate that CD1 and TCR engagement are re-
quired for the stimulatory effect of LPS.
Mechanism by which LPS Modulates Antigen
Presentation and T Cell Activation
The stimulatory capacity of infected or LPS-treated APCs
could be associated with increased surface expression
of CD1 antigen-presenting molecules and costimula-
tory molecules, collectively contributing to lowering of
the T cell activation threshold. This possibility was in-
vestigated by immunofluorescence analysis of expres-
sion of CD1 and costimulatory molecules. Expression
of all four CD1 molecules was slightly increased on DCs
upon LPS treatment as follows: CD1a, 26%; CD1b,
34%; CD1c, 30%; and CD1d, 18%. Moreover, the costi-
mulatory molecules B7.1 and CD40 were upregulated
by LPS treatment 27% and 40%, respectively. Thus,
upregulation of both costimulatory and CD1 antigen-
presenting molecules may contribute to the activation
of CD1-restricted T cells by LPS-treated DCs. However,
this mechanism alone is not sufficient, because DC
treatment with lipid A also induced similar upregulation
of CD1 and costimulatory molecules (data not shown)
but did not induce T cell activation (Figure 3D).
Next, we investigated whether the LPS effect is de-
pendent on metabolically active APCs. When DCs were
first fixed and then incubated with LPS and T cells, they
lost their stimulatory capacity (Figure 4D). This negative
effect of fixation was observed with two different LPSs.
However, when APCs were first incubated with LPS and
then washed and fixed, they retained the stimulatory
capacity (Figure 4E). A time kinetic analysis showed
that incubation with LPS for 1 hr before fixation was
already inducing low but significant activation and that
incubation for 4 hr was extremely effective (Figure 4E).
This was observed with all tested self-GSL-specific T
cell clones.
To investigate whether the LPS effect requires prod-
ucts present in the serum, DCs were primed with LPS
in serum-free conditions and used to stimulate T cells.
This type of culture did not affect LPS-mediated activa-
Immunity
766Table 1. List of Lipopolysaccharides and Free Lipids A Used in This Study
Mimicry by Saccharide Moiety
Bacterial Strain Source of Strain (Where Known) Reference
C. jejuni 16971.94GSH GBS isolate GM1 ganglioside (Prendergast et al., 1998)
(HS:41)
C. jejuni 260.94RXH (HS:41) GBS isolate GM1 ganglioside (Prendergast et al., 1998)
C. jejuni 28134.94GSH GBS isolate GM1 ganglioside (Prendergast et al., 1998)
(HS:41)
C. jejuni 176.83 (HS:41) Enteritis isolate GM1 ganglioside (Prendergast et al., 1998)
C. jejuni HS:19* Serostrain GD1a/GM1 ganglioside (Moran and Prendergast,
2001)
C. jejuni AZR 6491 (HS:23)* Miller-Fisher syndrome (GBS) GM3/GD2/GD3 ganglioside (Moran and Prendergast,
isolate 2001)
C. jejuni HS:2 aerotolerant* Laboratory-derived Absent (Hanniffy et al., 2001)
aerotolerant strain
C. jejuni HS:3* Serostrain Absent (Moran and Prendergast,
2001)
C. jejuni HS:6* Serostrain Unknown (Muldoon et al., 2002)
E. coli O55:B5 Serostrain Absent (Knirel and Kochetkov, 1994)
E. coli O111:B4 Serostrain Absent (Knirel and Kochetkov, 1994)
H. pylori NCTC 11637* Type strain (gastritis isolate) Terminal Lewis x, poly-Lewis x chain, poly-i (Aspinall et al., 1994)
antigen chain
H. pylori 442* Peptic ulcer isolate Terminal Lewis x or Lewis y, poly-Lewis x (Aspinall et al., 1999)
chain, poly-i antigen chain
H. pylori J178* Non-ulcer dyspepsia isolate Terminal H-1 antigen predominantly, poly- A.P.M., unpublished results
Lewis x chain
H. pylori AF1 Gastritis isolate Terminal Lewis y, poly-Lewis x chain (Knirel et al., 1999)
S. typhimurium SL1181 Enteritis isolate Absent (Knirel and Kochetkov, 1994)
S. minnesota Re-595 Mutant (Rietschel et al., 1984)
lipid A**
E. coli F-583 lipid A** Mutant (Rietschel et al., 1984)
*Additional active LPS tested (data not shown).
**Not active in T cell stimulation. Lipids A are composed as follows. S. minnesota Re-595: 2, 3-O-(16:0)-14:0; 3, 3-OH-14:0; 2’, 3-O-(14:0)-
14:0; 3’, 3-O-(12:0)-14:0; and E. coli F-583: 2, 3-OH-14:0; 3, 3-OH-14:0; 2’, 3-O-(12:0)-14:0; 3’, 3-O-(14:0)-14:0.tion of T cells (data not shown), thus suggesting two t
iimportant conclusions. First, lipid binding proteins
present in serum are not required to induce the T cell r
astimulatory capacity in DCs. Second, GSL present in
the serum are not responsible for activation of GSL- g
ispecific T cells. Thus, LPS primes only metabolically
active APCs, its effect occurs in a relatively short time, c
tand also in the absence of serum.
a
lLPS Increases Synthesis of Endogenous GSL
A possible mechanism for the increased capacity of
GAPCs to stimulate T cells is that bacterial infection or
treatment with microbial products enhances the syn- T
cthesis of endogenous GSL in APCs, among which are
those recognized by autoreactive T lymphocytes. To in- s
tvestigate this possibility, we studied the de novo syn-
thesis of glycosphingolipids in DCs and THP-1 cells af- w
mter bacterial infections or after treatment with LPS.
Glycolipids synthesized in treated and control cells c
Twere analyzed by following the incorporation of radio-
active galactose or acetic acid, which are incorporated r
tduring synthesis of the GSL saccharide or fatty acid
moieties, respectively. Labeled GSL were detected by u
aautoradiography after purification and separation by
thin-layer chromatography (TLC). Either B. subtilis or l
eS. aureus infection or LPS treatment induced an in-
creased GSL synthesis in both THP-1 (Figure 5) and t
lDCs (data not shown), as detected by using both 14C-
galactose (Figure 5A) and 14C-acetic acid (Figure 5B). L
GDifferences in incorporation of radioactivity were de-ected between different precursors and also between
nfections and LPS stimulation. Different GSL incorpo-
ated unequal amounts of 14C-galactose and 14C-acetic
cid, which is likely a result of different utilization of the
alactose and fatty acids salvage pathway. Interest-
ngly, infection and stimulation with LPS induced an in-
reased synthesis of different GSL, showing that infec-
ion with B. subtilis or S. aureus and LPS treatment
ffect de novo GSL synthesis in a different manner, at
east under the in vitro test conditions employed.
To identify and test whether de novo-synthesized
SL activate specific T cells, GSL from LPS-treated
HP-1 cells were separated on TLC plates. Bands
orresponding to reference sulfatide and GM1 were
craped from these plates, and compounds were ex-
racted. Each material was split into two groups that
ere used to stimulate T cell clones and to perform
ass spectrometry analyses, respectively. GM1-spe-
ific and sulfatide-specific T cells did react with the
LC-purified GSL as shown in Figures 5C and 5D,
espectively. Electrospray ionization (ESI)-mass spec-
rometry analyses confirmed the presence of GM1 (Fig-
re 5E) and sulfatide (Figure 5F) in the scraped and
ctive material. Multiple GSL forms bearing different
ong-chain fatty acids were identified. Furthermore,
ach GSL contained a C18 sphingosine base as de-
ected by MS-MS fragmentation (data not shown). Col-
ectively, these data show that bacterial infection and
PS treatment induce an increased synthesis of self-
SL, including sulfatide and GM1.
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767Figure 3. DCs Treated with Intact LPS and
Modified LPS Derived from Different Gram-
Negative Bacteria Stimulate CD1-Restricted
T Cells
DCs were incubated for 2 hr with LPS (1 g/
ml) derived from the indicated bacteria before
addition of the CD1a-restricted sulfatide-spe-
cific K34A12.1 (A) or CD1b-restricted GM1-
specific GG33A (B) T cell clones (closed bars).
As controls, DCs (hatched bars) or T cells
(open bars) were incubated with LPS sepa-
rately. Error bars represent ± SD.
(C) DCs were incubated with intact LPS from
C. jejuni strain 260.94RXH (,), strain
16971.94GSH (B), or strain 176.83 (); with
methylated LPS from C. jejuni strain
260.94RXH (%), strain 16971.94GSH (C), or
strain 176.83 (:); or with acetylated LPS
from C. jejuni strain 260.94RXH (■) before
addition of the CD1b-restricted GG33A T
cell clone.
(D) DCs were incubated with intact LPS from
C. jejuni strain 28134.94GSH (,) or strain
16971.94GSH (); with intact LPS from H. py-
lori strain AF1 (B); with delipidated LPS (car-
bohydrate moiety) from C. jejuni strain
28134.94GSH (■) or strain 16971.94GSH (:);
with delipidated LPS from H. pylori strain
AF1 (C); or with lipid A from E. coli (;) or
S. minnesota (%) before addition of T cell
clone GG33A. Released IL-4 ± SD is shown.
Data are representative of the results of five experiments (A and B) or three experiments (C and D), respectively. Similar results were obtained
when IFN-γ release was investigated (data not shown).The increased synthesis of endogenous GSL is not a
direct proof that it is responsible for activation of self-
reactive T cells. Therefore, to confirm the importance
of endogenously synthesized GSL for activation, T cell
activation was performed under conditions in which de
novo synthesis of GSL was inhibited. DCs were first
incubated with Fumonisin B1 (FB1), an inhibitor of the
enzyme sphingosine N-acyltransferase that is essential
for GSL synthesis (Wang et al., 1991), and then were
treated with LPS and used as APCs. FB1 treatment pro-
foundly affected the capacity of DCs to activate CD1a-
and CD1b-restricted T cells (Figures 6A and 6B). Impor-
tantly, the antigen-presentation capacity of the same
FB1-treated cells was not altered when exogenous sul-
fatide or GM1 were used to activate the GSL-specific T
cells (Figures 6C and 6D), thus excluding a nonspecific
effect of FB1 on antigen presentation. These results
confirm that synthesis of self-glycolipids is required for
activation of the tested T cells. Furthermore, they indi-
cate that it is unlikely that the TCRs, with fine specific-
ity for different self-glycolipids, crossreact to LPS,
P3CSK4, and LTA, which have different structures.
Finally, to investigate whether CD1 bound ligands are
involved in activation of T cells, we performed displace-
ment experiments. When LPS-treated APCs were incu-
bated with increasing doses of GSL that bind to CD1
but are not recognized by the T cell clones used in the
test, a profound reduction of T cell activation was de-
tected (Figures 6E and 6F). This was observed with T
cells specific either for CD1b-GM1 or for CD1a-sulfa-
tide, thus confirming that the appropriate endogenous
glycolipid must be present in the stimulatory CD1-GSL
complexes.Discussion
Autoimmune diseases such as MS and GBS are associ-
ated with infections, but the mechanisms responsible
for this etiological association are not completely under-
stood. To investigate whether bacterial infections may
contribute to activation of self-glycolipid-specific T cells,
we studied the reactivity of T cells isolated from patients
with MS and specific for GM1 ganglioside and sulfa-
tide. These T cells, which are CD1-restricted, were acti-
vated by APCs infected with different bacteria or treated
with different microbial products. The fact that different
infections (both gram-positive and -negative bacteria)
and treatments with differing microbial products confer
upon APCs the capacity to stimulate GSL-specific T
cells suggests that they have similar mechanisms of
action. These mechanisms require the presence of ap-
propriate CD1-presenting molecules, APC display of
specific GSL antigen, and TCR engagement, support-
ing the central importance of CD1-restricted antigen
recognition by TCR. These characteristics make our
findings different from the broad and antigen-nonspe-
cific LPS-induced T cell activation previously described
in a mouse experimental model (Mattern et al., 1999).
Most likely, bacteria and LPS exert multiple effects
on APCs, which together contribute to T cell stimula-
tion. An important effect is upregulation of CD1-pre-
senting molecules on the APC surface, as well as of B7
and CD40 costimulatory molecules, which both facili-
tate T cell activation. However, this upregulation is not
sufficient to activate autoreactive T cells, because
when the same APCs are treated with lipid A, which
likewise upregulates CD1, B7, and CD40 molecules, the
Immunity
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LPS-treated DCs were incubated with (A) anti-CD1a or isotype-matched control mAb before addition of the CD1a-restricted K34A12.1 T cell
clone, or (B) with anti-CD1b or isotype-matched control mAb before addition of the CD1b-restricted GG33A T cell clone. Fab fragments of
anti-CD3 mAb were also used. Error bars represent ± SD.
(C) CD1b-transfected (open symbols) or mock-transfected (closed symbols) THP-1 cells were incubated with the indicated concentrations of
LPS from C. jejuni strain 176.83 (B, C), C. jejuni strain 16971.94GSH (,, ■), or E. coli strain O55:B5 (, :) before the addition of CD1b-
restricted GG33A T cells.
(D) Live (open symbols) or fixed (closed symbols) DCs were incubated with the indicated concentrations of LPS from C. jejuni 260.94RXH (B,
C) or from C. jejuni 176.83 (,:) before addition of the T cell clone GG33A.
(E) DCs were incubated with LPS from C. jejuni 16971.94GSH for the indicated times. After extensive washing, DCs were fixed and used to
stimulate the CD1a-resricted T cell clone K34A12.1 (:) or the two CD1b-restricted T cell clones GG33A (C) and DS1C9b (■). Released
IL-4 ± SD is shown. Data are representative of the results of two experiments (A)–(C) or three experiments (D) and (E), respectively. Similar
results were obtained when IFN-γ release was investigated (data not shown). Release of IFN-γ was also assessed with each LPS and showed
similar results (data not shown).same T cell clones are not activated. An additional ef- r
Gfect is therefore required and is observed only in living
APCs. This is clearly indicated by the observation that e
twhen APCs are fixed and then stimulated with LPS,
they do not acquire the capacity to stimulate T cells. d
sOn the other hand, if APCs are first stimulated with the
microbial products and then fixed, they acquire and t
cmaintain the T cell stimulatory capacity, showing that
the cellular events induced by infection or LPS persist f
cin the APCs. These results exclude the possibility that
secretion of soluble factors by APCs is responsible for
lthis effect. Moreover, these data reveal an important
difference in the activation of iNKT cells observed after m
1LPS treatment and during S. typhimurium infection in
mice (Brigl et al., 2003). In this experimental model, i
ciNKT cells recognize a CD1d-presented, unknown self-
antigen, and their activation is dependent on the pres- 1
sence of IL-12 secreted by living APCs.
The kinetic studies we performed indicate that stimu- i
clation of living APCs for 4 hr allows acquisition of their
full stimulatory capacity. This suggests that some meta- n
abolic changes occur inside the stimulated APCs, which
may be responsible for the phenomenon. After incorpo- Wation of radioactive galactose and acetic acid into the
SL of stimulated APCs, we found that this important
ffect is the upregulation of GSL synthesis. Either infec-
ion, with B. subtilis or S. aureus, or LPS treatment in-
uces increased GSL synthesis, including GM1 ganglio-
ide and sulfatide, which are the self-antigens stimulating
he autoreactive T cells used in these studies. This was
onfirmed by the isolation and mass spectrometry identi-
ication of both GSLs, which also stimulated specific T
ells.
An indirect effect of LPS treatment on lipid metabo-
ism has already been attributed to TNF-α, which pro-
otes lipid metabolism (Haimovitz-Friedman et al.,
997; Hardardottir et al., 1994). Furthermore, in vivo and
n vitro LPS treatments directly increase activity of glu-
osylceramide synthase (Memon et al., 1998, 2001,
999), the enzyme involved in the initial step of GSL
ynthesis. It is likely that a similar mechanism is also
mplicated in the stimulation of GSL-autoreactive T
ells. In our experiments, the importance of endoge-
ous GSL synthesis is supported by inhibition with FB1,
drug that blocks GSL synthesis (Wang et al., 1991).
hen APCs were treated with FB1, a significant reduc-
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769Figure 5. Analysis of De Novo Synthesized
GSL
TLC of 14C-galactose- (A) and 14C-acetic
acid- (B) labeled lipids extracted from THP-1
cells treated with medium as control (C), with
LPS (10 g/ml), or infected with B. subtilis
(Bs) or with S. aureus (Sa). The bands corre-
sponding to sulfatide and GM1 are indicated
by arrows.
(C) INF-γ release (±SD) by the GM1-specific
GG33A T cell clone after stimulation with
DCs and an irrelevant TLC-scraped band
(Blank), the TLC-scraped GM1 (Scraped),
and purified GM1 (at 10 g/ml) as positive
control (Antigen).
(D) INF-γ release (±SD) by the sulfatide-spe-
cific K34B9.1 T cell clone after stimulation with
DCs and an irrelevant TLC-scraped band
(Blank), the TLC-scraped sulfatide (Scraped),
and purified sulfatide (at 100 ng/ml) as positive
control (Antigen).
(E) ESI-MS spectrum acquired in positive ion
mode of the GM1 band scraped from TLC.
Inset: table of sodiated GM1 ions and struc-
ture of fatty acid (FA) chains.
(F) ESI-MS spectrum acquired in negative
ion mode of a sulfatide band scraped from
TLC. Inset: table of sulfatide ions and struc-
ture of fatty acid chains. Abbreviations: h,
α-hydroxylated fatty acid chains; ND, not de-
termined.tion of T cell activation was observed. This effect is not
the consequence of a generic reduction of the antigen
presentation capacities, because FB1-treated APCs
present exogenously added GSL with equal efficiency
as nontreated cells.
In normal resting APC, endogenous GSL do not form
sufficient numbers of complexes with CD1 molecules,
as suggested by the lack of stimulation of self-GSL-
specific T cells (Shamshiev et al., 1999). After bacterial
infection, the increased amounts of available GSL may
facilitate the formation of enough CD1-GSL complexes
to lead to activation of T cells. An additional mecha-
nism, for which we do not have experimental evidence
at present, is that upon bacterial infection or LPS treat-
ment, CD1 molecules acquire new properties (i.e., dif-
ferent recycling kinetics, association with lipid-transfer
proteins, and persistence in intracellular compartments
rich in GSL) that promote loading with endogenous
GSL.
Collectively, these findings suggest that recognition
of induced self by infection is the important mechanism
leading to autoreactive T cell activation and, possibly,
participation in the pathogenesis of some autoimmune
diseases, such as MS and GBS, in which the anti-GSL
T cell response may be important.
Our studies have also shown that different live bacte-
ria as well as bacterial soluble cell wall and membrane
components induce activation of self-GSL-reactive T
cells. The microbial products tested in these studies
stimulate innate responses through different pattern-
recognition receptors (Kaisho and Akira, 2003). This
fact likely excludes the participation of a single innate
receptor but rather suggests the involvement of dif-
ferent receptors sharing signaling pathways, which thusupregulate GSL synthesis. A similar mechanism involv-
ing stimulation of APC surface receptors has been re-
cently proposed in mouse infection with S. typhimu-
rium, which is associated with the expansion of iNKT
cells after activation of MyD88- and Triff-dependent re-
ceptors (Mattner et al., 2005).
We have also found that an intact LPS structure is
required for activity because free lipid A from two dif-
ferent bacteria did not induce the T cell stimulatory ac-
tivity, despite the capacity to induce other responses in
stimulated monocytes. Furthermore, when LPSs from
C. jejuni or H. pylori were deglycosylated (thus yielding
the respective free lipid A molecules) or, conversely,
were delipidated (yielding the saccharide component),
they were no longer active. These observations assign
an important role to both the saccharide and lipid parts
of LPS. Alternatively, they indicate that a functional mo-
lecular conformation, which only occurs when both
moieties are present and bound in intact LPS, is re-
quired for activity. Further studies will be required to
investigate whether lack of activity of lipid A and degly-
cosylated LPS are due to insufficient activation of Toll-
like receptors and/or to the concomitant stimulation of
different innate receptors.
A final consideration regards the function of T cells
recognizing self-glycolipids in the context of CD1 mole-
cules. T cells reactive against self-polyisoprenyl glyco-
lipids (Moody, 2001), phospholipids (Gumperz et al.,
2000), gangliosides (Shamshiev et al., 1999, 2000), and
sulfatide (Jahng et al., 2004; Shamshiev et al., 2002)
have been identified and characterized. The reactivity
against gangliosides and sulfatide is rather common in
normal individuals that do not show clinical signs of
autoimmune phenomena but is more frequent in pa-
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Ccreased GSL Synthesis in APCs
The CD1b-restricted GM1-specific GG33A (A, C, E) T cell clones
Dand CD1a-restricted sulfatide-specific K34A12.1 (B, D, F) were
Dused. (A and B) DCs were incubated with LPS from C. jejuni
(260.94RXH with or without FB1, washed, fixed and used to stimu-
tlate T cells. (C and D) The same DCs treated (,) or untreated ()
iwith FB1 were fixed and used to stimulate the T cells in the pres-
Nence of GM1 (C) or sulfatide (D). (E and F) Displacement of CD1
abound ligands with GM3 ganglioside inhibits activation of GM1- (E)
Mand sulfatide-specific (F) T cells. Released IL-4 ± SD is shown. Re-
hsults are representative of three experiments. (A) p < 0.02; (B) p <
(0.05; (E) p < 0.02; (F) p < 0.05.
(
3tients with MS (Shamshiev et al., 1999). We propose a
Tdouble role for T cells recognizing induced self-GSL.
DDuring the initial phases of infections, these autoreac-
i
tive T cells might be readily activated to release cyto- p
kines at the place of infection or in the lymph node. (
This might be relevant for local antimicrobial protection w
tand immunoregulation during the priming of lympho-
icytes with other antigen specificities. However, in the
Labsence of infection, GSL autoreactive T cells might
e
also react to extracellular glycolipids if available in large e
amounts, as it occurs in MS brain lesions or in de- 1
graded axons in GBS. In these instances, the proinflam- w
wmatory function of self-GSL-reactive T cells could con-
mtribute to autoimmune diseases.
a
Experimental Procedures
F
DBacterial Products and GSLThe LPSs used in this study are listed in Table 1. Preparations of
C. jejuni LPS were purified from bacterial strains isolated from en-eritis or from GBS patients, and preparations of H. pylori LPS were
urified from gastric biopsy isolates, as described previously
Moran et al., 1991a). E. coli O55:B5 and O111:B4 LPS and S. typhi-
urium SL1181 LPS were purchased from Sigma (Buchs, Switzer-
and) and subjected to phenol reextraction. All the LPS prepara-
ions were of high purity, essentially free from proteins (<0.1%) and
ucleic acids (<0.1%). Modified LPS was produced after acetyla-
ion and methylation with the procedures described (Moran et al.,
991b). Delipidation and deglycosylation of LPS, to yield the carbo-
ydrate moiety of LPS and free lipid A, respectively, were per-
ormed by acid hydrolysis as described elsewhere (Moran et al.,
991a, 1991b). Lipid A from E. coli F-583 and S. minnesota Re-595
as obtained from Sigma. Sulfatide and GM1 were purchased from
atreya (Pleasant Gap, PA, USA). Purified ganglioside GM3 was
indly provided by S. Sonnino (University of Milano, Italy). All the
lycolipids were 98%–99% pure according to thin-layer chroma-
ography (TLC) analysis. P3CSK4 was kindly provided by Echaz
icrocollection AG (Tübingen, FRG), and LTA was provided by W.
ischer (Erlangen University, FRG).
Cell Clones and Antigen-Presenting Cells
M1- and sulfatide-specific T cell clones were derived as de-
cribed (Shamshiev et al., 1999, 2000, 2002). DCs were isolated
rom peripheral blood mononuclear cells by culturing in the pres-
nce of recombinant IL-4 and GM-CSF, as described previously
Porcelli et al., 1992). After 4 days of culture, DCs were tested for
he expression of CD1 molecules by using mAbs specific for CD1a
OKT6, ATCC Number CRL-8019; American Type Culture Collec-
ion), CD1b (WM-25, Immunokontakt, Lugano, Switzerland), and
D1c (L161, Instrumentation Laboratory, Schlieren, Switzerland).
he following cell lines were used as APCs in other experiments:
D1a-, CD1b-, or mock-trasfected C1R lymphoblastoma cells
kindly provided by S. Porcelli, Albert Einstein University, New
ork); CD1b-transfected THP-1 cells and CD1b-transfected HeLa
ells (kindly provided by T. Prigozy and M. Kronenberg, LIAI, La
olla, CA); and MOLT-4 T-lymphoma (ATCC Number CRL-1582).
PS- and lipid A-treated DCs were also stained with anti-CD1, anti-
D80 mAbs (B7.1, BD Pharmingen, Basel, Switzerland), and anti-
D40 mAb (BD Pharmingen).
C Infection
Cs were washed in phosphate-buffered saline (PBS) and plated
25 × 103/well) in medium without antibiotic in 96-well plates. Infec-
ion was performed by exposing DCs to E. coli (strain DH5α grown
n LB broth), B. subtilis (ATCC Number CRL-6051), S. aureus (ATCC
umber CRL-25904) (both grown in trypticase soy broth to station-
ry phase [12 hr]), or BCG (ATCC Number CRL-27290) (grown in
iddlebrook 7H9 liquid medium) at bacteria:DC ratios of 1:1 for 2
r. Thereafter, DCs were washed and cocultured with T cell clones
105 cells/well) in complete medium supplemented with gentamycin
5 g/ml) and kanamycin (50 g/ml). Supernatants were collected
6 hr later for IFN-γ and IL-4 determination.
Cell Activation Assays
Cs (5 × 104/well) or CD1b-transfected THP-1 cells (5 × 104/well)
n RPMI-1640 medium containing 10% fetal calf serum (FCS) were
reincubated for 2 hr at 37°C with LPS before addition of T cells
6 × 104/well in triplicate). Some experiments were done in medium
ithout FCS. Supernatants were harvested after 36 hr of incuba-
ion, and cytokine release was measured by using enzyme-linked
mmunosorbent assay (ELISA) kits (IFN-γ kit from Instrumentation
aboratory; TNF-α and IL-4 kits from BD Pharmingen). Data are
xpressed as mean pg/ml or ng/ml ± SD of triplicates. For blocking
xperiments, DCs were preincubated with LPS from C. jejuni
6971.94GSH (1 g/ml) at 37°C for 2 hr. Subsequently, preparations
ere incubated with 5 g/ml of anti-CD1a mAb, anti-CD1b mAb, or
ith 10 g/ml of Fab fragments of anti-CD3 (TR66) mAb for 20
in prior to addition of T cells. Anti-TCRVγ9 (B3) mAb was used as
n isotype-matched control.
ixation of DC
Cs were washed and suspended in PBS (2–3 × 106/ml) containing0.05% glutaraldehyde (Fluka, Buchs, Switzerland) for 30 s at 37°C.
Further fixation was blocked with 0.2 M lysine (Fluka). The effi-
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771ciency of fixation was controlled by loading fixed APCs with pro-
pidium iodide, and cytofluorimetry analysis was used to confirm
the absence of residual living cells. In some experiments, APCs
were first fixed, washed, and then incubated with LPS for 2 hr be-
fore addition of T cells.
Detection of De Novo GSL Synthesis
To detect de novo-synthesized glycolipids, DCs or THP-1 cells
were infected with B. subtilis or S. aureus at a 1:1 bacteria:cell ratio
or were treated with 100 ng/ml LPS from E. coli O55:B5 pulsed with
5 Ci of 14C-galactose or 14C-acetic acid (both purchased from
Amersham Biosciences) for 48 hr at 37°C. Subsequently, cells were
lysed, and glycolipids were extracted three times with chloro-
form:methanol (2:1, vol:vol). Silica gel 60 F-254 HPTLC plates
(Merck, Darmstadt, Germany) were loaded with 5 l of extracted
glycolipids corresponding to 250,000 cells, and plates were devel-
oped in a saturated chamber for 45 min with a mobile phase of
chloroform:methanol:0.25% KCl (50:40:10, vol:vol). Developed
plates were dried and exposed to Roentgen films for different times
to ensure optimal signal resolution. Each experiment was repeated
at least three times. In some experiments, preparative TLC was
performed with cell lysate from 9 × 107 THP-1 cells treated with 10
g/ml LPS. Bands corresponding to GM1 and sulfatide standards
were scraped from TLC plates, resuspended in 10 l methanol, and
used to activate specific T cells and to perform mass spectrome-
try analysis.
Mass Spectrometry
Mass spectrometry was done in both positive and negative ion
modes. ESI-tandem mass spectrometric analyses were performed
by using an ion trap Finnigan LTQ instrument (Finnigan, San Jose,
CA) equipped with an electrospray ion source and operated by
Xcalibur software. Samples were diluted in methanol prior to infus-
ing in the ESI source at 3 l/min, employing nitrogen as the nebuliz-
ing gas. In the negative ion mode, the heated capillary temperature
was 350°C, the electrospray needle was set at 4.5 kV with the skim-
mer at ground potential, and the sheath gas flow was approxi-
mately 35 arbitrary units. To enhance the signal of the (M-H)− ions in
the analyses, a voltage of 40 V was applied to the ion transmission
octapole. Collision-induced dissociation experiments were per-
formed in the ion trap with helium as the collision gas by applying
a collision energy of 45 eV on the sulfatide precursor ions. A full
scan covered the range from m/z 200 to 2000. All mass spectra
represent the average of 5–50 scans. In the positive mode, the cap-
illary temperature was set at 350°C, the needle voltage was set at
4.0 kV, and the sheath gas flow was approximately 20 arbitrary
units. For collision-induced dissociation experiments on GM1 pre-
cursor ions, 35 eV was applied. Due to its natural negative charge,
sulfatide gave a strong signal in the negative ion mode. It was ob-
served that in the positive ion mode for GM1, mass spectral inten-
sities of the sodiated adduct species were higher than those of the
corresponding deprotonated lipid species in the negative mode.
Inhibition of GSL Synthesis
DCs were preincubated with 10 g/ml of fumonisin B1 (FB1, Sigma)
for 20 hr, and then LPS from C. jejuni 260.94RXH was added and
further incubated for an additional 3 hr. After extensive washing,
cells were fixed with 0.05% glutaraldehyde (Fluka) for 30 s at 37°C,
treated with an equal volume of 0.2 M lysine (Fluka) to block further
fixation, and finally used to stimulate CD1-restricted T cells. The
efficiency of fixation was controlled by loading fixed APCs with
propidium iodide, and cytofluorimetry analysis was used to confirm
the absence of residual living cells.
Displacement of Endogenous GSL
Displacement of CD1 bound GSL was performed by using DCs pre-
treated with LPS (10 g/ml) for 3 hr at 37°C, which were washed
three times with PBS, fixed with 0.1% glutaraldedehyde, and plated
(4 × 104/well) with various doses of other GSL (6–60 M) for 1 hr
before addition of T cells (5 × 104/well). The T cell clone G2B9,
which is isopentenyl-pyrophosphate-specific and expresses the
TCR Vγ9Vδ2, was used as the negative control and was not inhib-
ited by addition of GSL.Statistical Analysis
Group comparisons were performed with the Student’s t test.
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